BACKGROUND: This prospective pilot single-institution study was undertaken to document the feasibility, safety, and efficacy of radioembolization of liver-dominant metastatic gastrointestinal cancer using 90Y glass microspheres. METHODS: Between June 2010 and October 2013, 42 adult patients (26 men, 16 women; median age 60 years) with metastatic chemotherapy-refractory unresectable colorectal (n=21), neuroendocrine (n=11), intrahepatic bile duct (n=7), pancreas (n=2), and esophageal (n=1) carcinomas underwent 60 lobar or segmental administrations of 90Y glass microspheres. Data regarding clinical and laboratory adverse events (AE) were collected prospectively for up to 5.5 years after radioembolization. Radiographic responses were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Time to maximum response, response duration, progression-free survival (PFS) (hepatic and extrahepatic), and overall survival (OS) were measured. RESULTS: Median target dose and activity were 109.4 Gy and 2.6 GBq per treatment session, respectively. Majority of clinical AE were grade 1 or 2 in severity. Patients with colorectal cancer had hepatic objective response rate (ORR) of 25% and a hepatic disease control rate (DCR) of 80%. Median PFS and OS were 1.0 and 4.4 months, respectively. Patients with neuroendocrine tumors (NET) had hepatic ORR and DCR of 73% and 100%, respectively. Median PFS was 8.9 months for this cohort. DCR and median PFS and OS for patients with cholangiocarcinoma were 86%, 1.1 months, and 6.7 months, respectively. CONCLUSIONS: 90Y glass microspheres device has a favorable safety profile, and achieved prolonged disease control of hepatic tumor burden in a subset of patients, including all patients enrolled in the neuroendocrine cohort.
BACKGROUND: This prospective pilot single-institution study was undertaken to document the feasibility, safety, and efficacy of radioembolization of liver-dominant metastatic gastrointestinal cancer using 90Y glass microspheres. METHODS: Between June 2010 and October 2013, 42 adult patients (26 men, 16 women; median age 60 years) with metastatic chemotherapy-refractory unresectable colorectal (n=21), neuroendocrine (n=11), intrahepatic bile duct (n=7), pancreas (n=2), and esophageal (n=1) carcinomas underwent 60 lobar or segmental administrations of 90Y glass microspheres. Data regarding clinical and laboratory adverse events (AE) were collected prospectively for up to 5.5 years after radioembolization. Radiographic responses were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Time to maximum response, response duration, progression-free survival (PFS) (hepatic and extrahepatic), and overall survival (OS) were measured. RESULTS: Median target dose and activity were 109.4 Gy and 2.6 GBq per treatment session, respectively. Majority of clinical AE were grade 1 or 2 in severity. Patients with colorectal cancer had hepatic objective response rate (ORR) of 25% and a hepatic disease control rate (DCR) of 80%. Median PFS and OS were 1.0 and 4.4 months, respectively. Patients with neuroendocrine tumors (NET) had hepatic ORR and DCR of 73% and 100%, respectively. Median PFS was 8.9 months for this cohort. DCR and median PFS and OS for patients with cholangiocarcinoma were 86%, 1.1 months, and 6.7 months, respectively. CONCLUSIONS: 90Y glass microspheres device has a favorable safety profile, and achieved prolonged disease control of hepatic tumor burden in a subset of patients, including all patients enrolled in the neuroendocrine cohort.
Authors: Khairuddin Memon; Robert J Lewandowski; Mary F Mulcahy; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Vanessa L Gates; Bassel Atassi; Steven Newman; Reed A Omary; Al B Benson; Riad Salem Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-02 Impact factor: 7.038
Authors: Mohamed H K Abdelmaksoud; John D Louie; Nishita Kothary; Gloria L Hwang; William T Kuo; Lawrence V Hofmann; David M Hovsepian; Daniel Y Sze Journal: J Vasc Interv Radiol Date: 2011-10 Impact factor: 3.464
Authors: Alain Hendlisz; Marc Van den Eynde; Marc Peeters; Geert Maleux; Bieke Lambert; Jaarke Vannoote; Katrien De Keukeleire; Chris Verslype; Luc Defreyne; Eric Van Cutsem; Philippe Delatte; Thierry Delaunoit; Nicola Personeni; Marianne Paesmans; Jean-Luc Van Laethem; Patrick Flamen Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544
Authors: Andrew S Kennedy; Douglas Coldwell; Charles Nutting; Ravi Murthy; Daniel E Wertman; Stephen P Loehr; Carroll Overton; Steven Meranze; Jerry Niedzwiecki; Scott Sailer Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-01 Impact factor: 7.038
Authors: Philipp M Paprottka; Ralf-T Hoffmann; Alexander Haug; Wieland H Sommer; Franziska Raessler; Christoph G Trumm; Gerwin P Schmidt; Nima Ashoori; Maximilian F Reiser; Tobias F Jakobs Journal: Cardiovasc Intervent Radiol Date: 2011-08-17 Impact factor: 2.740
Authors: Samdeep Mouli; Khairuddin Memon; Talia Baker; Al B Benson; Mary F Mulcahy; Ramona Gupta; Robert K Ryu; Riad Salem; Robert J Lewandowski Journal: J Vasc Interv Radiol Date: 2013-04-19 Impact factor: 3.464
Authors: Andrew S Kennedy; William A Dezarn; Patrick McNeillie; Doug Coldwell; Charles Nutting; Dennis Carter; Ravi Murthy; Steven Rose; Richard R P Warner; David Liu; Holger Palmedo; Carroll Overton; Bonita Jones; Riad Salem Journal: Am J Clin Oncol Date: 2008-06 Impact factor: 2.339
Authors: H A Ziessman; J H Thrall; J W Gyves; W D Ensminger; J E Niederhuber; M Tuscan; S Walker Journal: J Nucl Med Date: 1983-10 Impact factor: 10.057
Authors: Gary W Nace; Jennifer L Steel; Nikhil Amesur; Albert Zajko; Bryon E Nastasi; Judith Joyce; Michael Sheetz; T Clark Gamblin Journal: Int J Surg Oncol Date: 2011-03-20
Authors: Anna-Karin Elf; Mats Andersson; Olof Henrikson; Oscar Jalnefjord; Maria Ljungberg; Johanna Svensson; Bo Wängberg; Viktor Johanson Journal: World J Surg Date: 2018-02 Impact factor: 3.352